Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis. [More]
FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). [More]
UC San Diego-led research team awarded $1.89 million to carry out research on leptospirosis

UC San Diego-led research team awarded $1.89 million to carry out research on leptospirosis

An international research team, headed by Joseph Vinetz, MD, professor of medicine at University of California, San Diego School of Medicine and director of the UC San Diego Center for Tropical Medicine and Travelers Health, has been awarded a 5-year, $1.89 million cooperative agreement to carry out translational research studies of leptospirosis, an infectious and sometimes fatal bacterial disease endemic in much of the world. [More]
Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942. [More]
Global 'Call to Action Summit 2015' adopts DELHI DECLARATION to end preventable maternal and child deaths

Global 'Call to Action Summit 2015' adopts DELHI DECLARATION to end preventable maternal and child deaths

The two-day global 'Call to Action Summit 2015' concluded today with Health Ministers and heads of country delegations from 22 countries adopting the DELHI DECLARATION on 'ending preventable maternal and child deaths'. The declaration was developed as an outcome of the high-level ministerial conclave held yesterday during the summit. [More]
Oysters play important role in persistence and transmission of norovirus

Oysters play important role in persistence and transmission of norovirus

Oysters not only transmit human norovirus; they also serve as a major reservoir for these pathogens, according to research published August 28 in Applied and Environmental Microbiology, a journal of the American Society for Microbiology. "More than 80 percent of human norovirus genotypes were detected in oyster samples or oyster-related outbreaks," said corresponding author Yongjie Wang, PhD. [More]
Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies. [More]

Single dose of oral cholera vaccine could save more lives in crisis situations

An oral cholera vaccine that is in short supply could treat more people and save more lives in crisis situations, if one dose were dispensed instead of the recommended two, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

The American Gastroenterological Association, in partnership with the Crohn's & Colitis Foundation of America and Janssen Biotech, Inc., announced today that Theresa Alenghat, VMD, PhD, from Cincinnati Children's Hospital Medical Center, OH, was awarded with the 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease (IBD) Epigenetics Research. [More]
Flu remedies can help treat E. coli bacteria

Flu remedies can help treat E. coli bacteria

If the intestinal bacteria level becomes unbalanced, it can cause diseases. Physiologists from the University of Zurich reveal how a specific carbohydrate in the intestinal mucosa heavily multiplies certain E. coli bacteria and thus causes inflammations. These could be treated with flu remedies, which opens up new therapeutic possibilities. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Researchers develop two simple tools to assess dehydration severity in children

Researchers develop two simple tools to assess dehydration severity in children

Dehydration from diarrhea, either from viral infection or cholera, accounts for 10 percent of all child deaths worldwide. Though it's a pervasive problem, there are no clinical guidelines that perform better than chance for assessing dehydration severity. In a new study, a team of researchers report that they statistically derived two simple diagnostic tools with high sensitivity and specificity from the cases of 771 children aged 0 to 5 in Dhaka, Bangladesh. [More]
No single genetic strain associated with the worst cases of C. difficile infections

No single genetic strain associated with the worst cases of C. difficile infections

No single genetic strain of the widespread Clostridium difficile (C. difficile) bacteria appears to be any more harmful than other strains, according to new research published online today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. [More]
Scientists create membrane capable of detecting organisms that trigger diarrhea, intestinal problems

Scientists create membrane capable of detecting organisms that trigger diarrhea, intestinal problems

A group of scientists from the Institute of Ecology and the Faculty of Medicine of the National University of Mexico, created a membrane capable of simultaneously detecting numerous organisms in the water or food that cause diarrhea and intestinal problems. This health problem annually kills 760 000 children under the age of five, according to the World Health Organization. [More]
Contact precaution use needs to be individualized to fit hospital's specific needs and resources

Contact precaution use needs to be individualized to fit hospital's specific needs and resources

Contact precautions are recommended by the Centers for Disease Control and Prevention for all patients known to be infected with or carrying multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Yet, the use of contact precautions--which require a patient to be isolated in a single hospital room and health care providers to wear a gown and gloves when caring for patients--is widely debated in the medical community. [More]
Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. [More]
Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015. [More]
Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder. [More]
Advertisement